- Home
- WY vs GMAB Comparison
WY vs GMAB Comparison
Compare WY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WY
- GMAB
- Stock Information
- Founded
- WY 1900
- GMAB 1999
- Country
- WY United States
- GMAB Denmark
- Employees
- WY N/A
- GMAB N/A
- Industry
- WY Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- WY Real Estate
- GMAB Health Care
- Exchange
- WY Nasdaq
- GMAB Nasdaq
- Market Cap
- WY 18.0B
- GMAB 17.4B
- IPO Year
- WY N/A
- GMAB N/A
- Fundamental
- Price
- WY $23.04
- GMAB $28.66
- Analyst Decision
- WY Buy
- GMAB Strong Buy
- Analyst Count
- WY 8
- GMAB 7
- Target Price
- WY $31.00
- GMAB $41.50
- AVG Volume (30 Days)
- WY 5.9M
- GMAB 2.6M
- Earning Date
- WY 10-30-2025
- GMAB 11-06-2025
- Dividend Yield
- WY 3.64%
- GMAB N/A
- EPS Growth
- WY N/A
- GMAB 77.72
- EPS
- WY 0.46
- GMAB 21.62
- Revenue
- WY $7,072,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- WY $0.04
- GMAB $24.92
- Revenue Next Year
- WY $3.97
- GMAB $15.97
- P/E Ratio
- WY $50.52
- GMAB $1.33
- Revenue Growth
- WY N/A
- GMAB 32.97
- 52 Week Low
- WY $22.29
- GMAB $17.24
- 52 Week High
- WY $32.70
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- WY 42.02
- GMAB 40.06
- Support Level
- WY $22.29
- GMAB $28.08
- Resistance Level
- WY $23.72
- GMAB $29.35
- Average True Range (ATR)
- WY 0.49
- GMAB 0.65
- MACD
- WY -0.03
- GMAB -0.27
- Stochastic Oscillator
- WY 43.68
- GMAB 25.93
About WY Weyerhaeuser Company
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.